AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1832261 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 55
Study 6619271 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg, iv) administered at 1100 h
Number of subjects: 21
Study 6619271 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg, iv) administered at 2300 h
Number of subjects: 21
Study 6376722 — intervention group
Group type: COMPARATOR
Intervention: melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks)
Number of subjects: 234
Study 6376722 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan and prednisone at the same doses plus cyclophosphamide (600 mg/m2 intravenously every four weeks), MeCCNU (100 mg/m2 PO every eight weeks), and vincristine (0.6 mg/m2 IV every four weeks)
Number of subjects: 234
Study 30132244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 469
Study 30132244 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 469
Study 26611332 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 75
Study 26611332 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 75
Study 24944134 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training (FG)
Number of subjects: 57
Study 24944134 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 57
Study 21945362 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic melatonin
Number of subjects: 24
Study 21945362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20197012 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630 (1-6 years: 3 x 10 drops/d; > 6-12 years: 3 x 20 drops/d; > 12-18 years: 3 x 30 drops/d)
Number of subjects: 200
Study 20197012 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 200
Study 20197012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18502109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil for HTG
Number of subjects: 0
Study 18502109 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin or Simvastatin for HCHL
Number of subjects: 0
Study 18502109 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (Atorvastatin, Simvastatin, Gemfibrozil)
Number of subjects: 0
Study 18502109 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 0
Study 15818718 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported data from health economic questionnaire
Number of subjects: 234
Study 15818718 — intervention group
Group type: COMPARATOR
Intervention: Payer-derived data from insurance claims
Number of subjects: 234
Study 15818718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both patient-reported and payer-derived data
Number of subjects: 234
Study 12766097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft
Number of subjects: 314
Study 12766097 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional therapy)
Number of subjects: 314
Study 10571355 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia plus 0.5 ml preservative-free 1% intracameral lidocaine
Number of subjects: 204
Study 10571355 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia plus 0.5 ml intracameral balanced salt solution
Number of subjects: 204
Study 8545227 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-1 (monovalent serotype 1)
Number of subjects: 1278
Study 8545227 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV (tetravalent)
Number of subjects: 1278
Study 8545227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278
Study 1859055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral killed Haemophilus influenzae vaccine
Number of subjects: 62
Study 1859055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 6138009 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride 30 mg
Number of subjects: 0
Study 6138009 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride 60 mg
Number of subjects: 0
Study 6138009 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride 90 mg
Number of subjects: 0
Study 6138009 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride (30, 60, 90 mg)
Number of subjects: 0
Study 31290965 — intervention group
Group type: COMPARATOR
Intervention: Esketamine 84 mg plus oral antidepressant
Number of subjects: 346
Study 31290965 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg plus oral antidepressant
Number of subjects: 346
Study 31290965 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral antidepressant
Number of subjects: 346
Study 28816150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg with WBRT (n=5)
Number of subjects: 16
Study 28816150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg with SRS (n=11)
Number of subjects: 16
Study 28816150 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 16
Study 25413313 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in 27 patients with LVI-positive tumors.
Number of subjects: 499
Study 25413313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphovascular invasion (LVI) presence in tumors.
Number of subjects: 499
Study 23825035 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Iyengar yoga program (twice weekly) with fall prevention education booklet
Number of subjects: 54
Study 23825035 — intervention group
Group type: COMPARATOR
Intervention: Control group (education booklet only)
Number of subjects: 54
Study 21752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Determine HIV‐1/2 assay
Number of subjects: 1398
Study 21752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory testing results at ITM
Number of subjects: 1398
Study 21752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Second blood specimen testing
Number of subjects: 1398
Study 21752945 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing algorithm with R/S assays
Number of subjects: 1398
Study 19358730 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care visit with physician discussion about alcohol
Number of subjects: 173
Study 16971315 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 3 consecutive days a week for 1 month, then 250 mg every other day for 2 months
Number of subjects: 290
Study 16971315 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 1 g daily for 1 month, then 500 mg daily for 2 months
Number of subjects: 290
Study 15179210 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (Metoprolol)
Number of subjects: 80
Study 15179210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11722956 — intervention group
Group type: COMPARATOR
Intervention: Methionine intake of 0 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study 11722956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 6.5 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study 11722956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 13.0 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study 11722956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 19.5 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study 11722956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 26.0 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study 11722956 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 32.0 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study 9463982 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulary for NSAIDs
Number of subjects: 10
Study 9463982 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 10
Study 8162931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-perfusion lung scintigraphy interpretation by experienced clinical physiologists
Number of subjects: 87
Study 8162931 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple scheme for deciding segmental ventilation-perfusion mismatch
Number of subjects: 87
Study 3145358 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation with increased doses from 36 to 46 Gy and accelerated split course hyperfractionation with simultaneous chemotherapy.
Number of subjects: 76
Study 3145358 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation of radiotherapy (control group).
Number of subjects: 76
Study 31226721 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 160 mg
Number of subjects: 332
Study 31226721 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 80 mg
Number of subjects: 332
Study 31226721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study 31226721 — intervention group
Group type: EXPERIMENTAL
Intervention: Revacept 160 mg, Revacept 80 mg, or Placebo
Number of subjects: 332
Study 27930611 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization intervention in intervention villages
Number of subjects: 2356
Study 27930611 — intervention group
Group type: COMPARATOR
Intervention: Control group (no community mobilization intervention)
Number of subjects: 2356
Study 25532433 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified D2 lymphadenectomy (D1+)
Number of subjects: 73
Study 25532433 — intervention group
Group type: COMPARATOR
Intervention: Standard D2 lymphadenectomy
Number of subjects: 73
Study 25532433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 73
Study 22460183 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and azathioprine (3 intravenous pulses of methylprednisolone 1 g at months 1, 3, and 5; oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for 6 months, followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further 6 months)
Number of subjects: 253
Study 22460183 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (26 patients)
Number of subjects: 253
Study 22460183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (whole population)
Number of subjects: 253
Study 22460183 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and azathioprine (group 1)
Number of subjects: 253
Study 22460183 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (group 2)
Number of subjects: 253
Study 21570870 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin plus aspirin (5 IU every other day for six doses)
Number of subjects: 129
Study 21570870 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (100 mg/d)
Number of subjects: 129
Study 21570870 — intervention group
Group type: EXPERIMENTAL
Intervention: Batroxobin plus aspirin
Number of subjects: 129
Study 21570870 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 129
Study 18496519 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 83
Study 18496519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 17215606 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage (auditory, tactile/kinesthetic, and visual stimulation) for 4 weeks
Number of subjects: 52
Study 12627740 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training (ST)
Number of subjects: 229
Study 12627740 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 229
Study 11180027 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg of morphine
Number of subjects: 10
Study 11180027 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 mg/70 kg of M6G
Number of subjects: 10
Study 11180027 — intervention group
Group type: EXPERIMENTAL
Intervention: 30.6 mg/70 kg of M3G
Number of subjects: 10
Study 11180027 — intervention group
Group type: EXPERIMENTAL
Intervention: 30.6 mg/70 kg of M3G with 10 mg/70 kg of morphine
Number of subjects: 10
Study 11180027 — intervention group
Group type: EXPERIMENTAL
Intervention: 30.6 mg/70 kg of M3G with 3.3 mg/70 kg of M6G
Number of subjects: 10
Study 11180027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9382506 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative 50 Gy radiation therapy to pelvic wall
Number of subjects: 110
Study 9382506 — intervention group
Group type: COMPARATOR
Intervention: No radiation therapy
Number of subjects: 110
Study 9382506 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications in radiation therapy group
Number of subjects: 110
Study 8436755 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral measures of heart period variability (RR variability)
Number of subjects: 0
Study 3706373 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassurance debriefing
Number of subjects: 296
Study 3706373 — intervention group
Group type: COMPARATOR
Intervention: Traditional arousal debriefing
Number of subjects: 296
Study 3706373 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite health education programs
Number of subjects: 296
Study 3706373 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 296
Study 3706373 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety levels
Number of subjects: 296
Study 29127153 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 45
Study 29127153 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscope
Number of subjects: 45
Study 26995778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Number of subjects: 28
Study 26995778 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 28
Study 24886037 — intervention group
Group type: EXPERIMENTAL
Intervention: Navicular Drop Test (NDT)
Number of subjects: 42
Study 24886037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Joint Dorsiflexion Test (AJD)
Number of subjects: 42
Study 24886037 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension MTP1 Test
Number of subjects: 42
Study 24886037 — intervention group
Group type: COMPARATOR
Intervention: Comparison of female and male runners
Number of subjects: 42
Study 22789149 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient communication skill training
Number of subjects: 194
Study 22789149 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician communication skill training
Number of subjects: 194
Study 21099157 — intervention group
Group type: EXPERIMENTAL
Intervention: CPN applied for 30 seconds
Number of subjects: 0
Study 21099157 — intervention group
Group type: EXPERIMENTAL
Intervention: CPN applied for 20 seconds followed by water rinsing
Number of subjects: 0
Study 21099157 — intervention group
Group type: COMPARATOR
Intervention: Etching with 10% citric acid‐3% FeCl(3) solution
Number of subjects: 0
Study 21099157 — intervention group
Group type: EXPERIMENTAL
Intervention: CPN applied for 10, 20, 30, or 60 seconds
Number of subjects: 0
Study 21099157 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with CPN for 10, 20, 30, or 60 seconds followed by etching
Number of subjects: 0
Study 18503922 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 22
Study 18503922 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 22
Study 15897362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril, 10 mg once daily for 24 weeks
Number of subjects: 40
Study 15897362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramiprilat in cell culture
Number of subjects: 40
Study 14570950 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg gefitinib
Number of subjects: 221
Study 14570950 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg gefitinib
Number of subjects: 221
Study 14570950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of gefitinib
Number of subjects: 221
Study 10364865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + Alfentanil (5 micrograms.kg‐1)
Number of subjects: 100
Study 10364865 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol + Alfentanil (5 micrograms.kg‐1)
Number of subjects: 100
Study 10364865 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.5 mg.kg‐1)
Number of subjects: 100
Study 10364865 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (> 7% in the inspiratory gas)
Number of subjects: 100
Study 8678385 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide nasal spray 0.06% (two 42-micrograms sprays per nostril)
Number of subjects: 411
Study 8678385 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide nasal spray 0.06%
Number of subjects: 411
Study 8500918 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 5
Study 8500918 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 5
Study 8500918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3540301 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group instruction in addition to large-group lectures
Number of subjects: 0
Study 3540301 — intervention group
Group type: COMPARATOR
Intervention: Large-group lectures only
Number of subjects: 0
Study 30842084 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment for more than 5 years
Number of subjects: 10
Study 30842084 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 10
Study 29342952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacadia® nature-based therapy (NNBT)
Number of subjects: 84
Study 29342952 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (STreSS)
Number of subjects: 84
Study 27724992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral spray vitamin D3 (3000 IU daily for 4 weeks)
Number of subjects: 22
Study 27724992 — intervention group
Group type: COMPARATOR
Intervention: Capsule vitamin D3 (3000 IU daily for 4 weeks)
Number of subjects: 22
Study 26228164 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care anxiety management program
Number of subjects: 503
Study 23597332 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeled group (informed of prehypertension)
Number of subjects: 100
Study 23597332 — intervention group
Group type: COMPARATOR
Intervention: Unlabeled group (not informed of prehypertension)
Number of subjects: 100
Study 20873898 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group cognitive-behavioral preventive intervention
Number of subjects: 111
Study 20873898 — intervention group
Group type: COMPARATOR
Intervention: Written information comparison condition
Number of subjects: 111
Study 18441679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenspiride in combination with broncholytic drugs for 6 months
Number of subjects: 68
Study 18441679 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COPD
Number of subjects: 68
Study 16800987 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodesoxycholic acid (UDA)
Number of subjects: 27
Study 16800987 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of LDL and UDA (LDL + UDA)
Number of subjects: 27
Study 16800987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidanling (LDL)
Number of subjects: 27
Study 16800987 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Control group)
Number of subjects: 27
Study 12684720 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate planimetric method (APM) for estimating lesion size using DWI
Number of subjects: 40
Study 12684720 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate planimetric method (APM) for estimating lesion size using FLAIR
Number of subjects: 40
Study 10231255 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational package intervention
Number of subjects: 1001
Study 10231255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational package)
Number of subjects: 1001
Study 10231255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid with norethisterone
Number of subjects: 1001
Study 10231255 — intervention group
Group type: EXPERIMENTAL
Intervention: Practices with fewer than 10 cases
Number of subjects: 1001
Study 7702138 — intervention group
Group type: EXPERIMENTAL
Intervention: Double burst stimulation with vecuronium 0.2 mg.kg‐1 in group A
Number of subjects: 60
Study 7702138 — intervention group
Group type: EXPERIMENTAL
Intervention: Double burst stimulation with vecuronium 0.2 mg.kg‐1 in group B
Number of subjects: 60
Study 2568783 — intervention group
Group type: EXPERIMENTAL
Intervention: Iotrolan 190
Number of subjects: 100
Study 2568783 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid-diluted iotrolan 300
Number of subjects: 100
Study 578480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ASA
Number of subjects: 10
Study 578480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31225537 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar-Incisor Hypomineralisation (MIH)
Number of subjects: 779
Study 31225537 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries
Number of subjects: 779
Study 31225537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorosis
Number of subjects: 779
Study 28056202 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 1095
Study 28056202 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus pertuzumab
Number of subjects: 1095
Study 28056202 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus taxane
Number of subjects: 1095
Study 24955752 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-160 mg/d)
Number of subjects: 1330
Study 24955752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1330
Study 23211552 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0 M)
Number of subjects: 20
Study 23211552 — intervention group
Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.5 M)
Number of subjects: 20
Study 23211552 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate meglumine (0.5 M)
Number of subjects: 20
Study 21262858 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 5 mg
Number of subjects: 42